DaVita Inc. Lifts Guidance After Earnings Beat
DaVita Inc. ((DVA)) has held its Q1 earnings call. Read on for the main highlights of the call.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
DaVita Inc. struck a cautiously upbeat tone on its latest earnings call, as management highlighted a clear beat on first-quarter expectations and raised full‑year guidance despite visible headwinds. Executives framed the period as proof that productivity initiatives and technology investments are starting to pay off, even as higher G&A, IKC losses and reimbursement uncertainty temper near‑term enthusiasm.
Q1 Earnings Beat on Operating Income and EPS
DaVita delivered adjusted operating income of $482 million and adjusted EPS of $2.87, with operating income landing about $50 million ahead of internal forecasts. Management said roughly half of the upside came from true operational outperformance and half from timing, suggesting some but not all of the strength may prove recurring.
Full-Year Guidance Raised and Narrowed
Management raised and narrowed its 2026 outlook, now targeting adjusted operating income of $2.15 billion to $2.25 billion and adjusted EPS of $14.10 to $15.20. The higher midpoint is driven mainly by a better volume outlook and lower patient care costs, underscoring confidence that operational improvements are sustainable.
Volume Trends and Utilization Improvement
Treatment volumes came in slightly ahead of forecast, with treatments per normalized day up about 40 basis points year over year in the first quarter. For the full year, DaVita now expects overall treatment volume to grow 25 to 50 basis points, which equates to 50 to 75 basis points growth on a normalized day basis.
Revenue per Treatment Showing Momentum
Revenue per treatment increased roughly 4% year over year in the quarter, with management citing an improvement of about $17.50 per treatment. Executives attributed around two thirds of the gain to normal rate and mix factors and the remainder to timing, implying some moderation later in the year.
Cost Productivity Supports Margin Expansion
Patient care cost per treatment was roughly flat compared with the prior quarter and came in better than expected, helped by productivity gains across the network. These cost controls, layered on top of revenue growth, are helping to support margin expansion even as the company spends heavily on technology.
IKC Delivers Strong Clinical and Savings Outcomes
DaVita’s Integrated Kidney Care business reported year‑over‑year gains across three key CKCC measures, reinforcing its value‑based care credentials. The company said it generated the highest total aggregate savings of any participant in the program, supported by a 4.5% improvement in gross savings rate since inception.
Capital Allocation and Balance Sheet Discipline
The company repurchased about 5 million shares, including 3 million in the first quarter and 2 million after quarter‑end in a transaction that involved Berkshire Hathaway. Leverage stood at 3.34 times consolidated EBITDA, comfortably within the stated target range of 3.0 to 3.5 times, giving DaVita flexibility for further capital returns.
Technology and AI as Strategic Growth Drivers
DaVita is ramping investment in modern data infrastructure and artificial intelligence tools to enhance caregiver productivity and operational efficiency. Management highlighted applications such as the ScheduleHub scheduling platform and a proprietary electronic medical record system as key enablers of scale benefits over time.
Rising G&A from Technology Investments
U.S. dialysis G&A rose by about $37 million year over year, a roughly 13% increase compared with the prior‑year quarter. Executives acknowledged that G&A is growing faster than revenue but framed the step‑up in technology and professional fees as a deliberate, strategic investment for long‑term advantage.
IKC Still in Investment Mode with Operating Loss
Despite its strong clinical and savings profile, IKC reported an adjusted operating loss of $19 million in the first quarter, in line with internal expectations. Management positioned IKC as a business in ramp‑up mode where near‑term losses are acceptable in pursuit of long‑term value creation in value‑based kidney care.
Slight Decline in Treatments Year over Year
Overall treatment volumes declined around 20 basis points compared with the same quarter last year, and admissions came in lower than expected. Some of this weakness was offset by inflows from Fresenius clinic closures, which helped support DaVita’s networks but did not fully erase the year‑over‑year decline.
ACA Enrollment and Mix Risk Loom Over RPT
Affordable Care Act open enrollment trends are slightly better than DaVita had anticipated, potentially reducing a previously assumed headwind. However, a shift toward lower‑tier bronze plans could raise patients’ out‑of‑pocket burden and modestly pressure revenue per treatment, leading management to keep its roughly $40 million headwind assumption intact for now.
RPT Growth Expected to Slow After Strong Q1
Despite the roughly 4% revenue per treatment growth posted in the quarter, DaVita continues to guide to only 1% to 2% RPT growth for the full year. The company expects commercial mix pressure and timing factors to weigh on pricing metrics as the year progresses, tempering the strong early‑year run‑rate.
Free Cash Flow and Interest Expense Headwinds
Free cash flow reached $140 million in the quarter, but management chose not to lift full‑year free cash flow guidance, citing higher variability in this metric. Quarterly interest expense was about $145 million and is expected to remain at similar levels for the rest of the year, leaving full‑year debt costs roughly flat with last year even after share repurchases.
Guidance and Outlook
Looking ahead, DaVita’s updated guidance embeds modest treatment volume growth, low‑single‑digit revenue per treatment gains and continued progress on patient care costs. While IKC remains a drag on near‑term profits and ACA mix risk lingers, management’s raised earnings outlook, stable leverage profile and ongoing technology investments point to a cautiously constructive setup for the remainder of the year.
DaVita’s latest earnings call painted the picture of a company using a solid operating beat to fund an ambitious transformation agenda. For investors, the story now hinges on whether productivity gains, AI‑driven efficiencies and the evolving IKC platform can more than offset reimbursement and mix headwinds, turning today’s investments into durable earnings power over the next few years.
